Sarepta Therapeutics, Inc.

Sarepta Therapeutics Misses on Revenue, Stock Down 1.69%

Sarepta Therapeutics reported a wider-than-expected loss per share, which was better than analysts anticipated. However, the lack of revenue details and no guidance updates led to a negative stock reaction, with shares dropping 1.69%. Investors may be concerned about the company's ability to generate revenue in the near term, especially given the ongoing challenges mentioned by management.